

Global mRNA Vaccines and Therapeutics Market: Focus on Application, mRNA Type, Country Data (13 Countries), and Competitive Landscape - Analysis and Forecast, 2021-2031

<https://marketpublishers.com/r/G6B8AC84A84DEN.html>

Date: May 2021

Pages: 207

Price: US\$ 5,250.00 (Single User License)

ID: G6B8AC84A84DEN

Abstracts

Hard copy option is available on any of the options above at an additional charge of \$500. Please email us at order@marketpublishers.com with your request.

Market Report Coverage - mRNA Vaccines and Therapeutics

Market Segmentation

Application – COVID-19 mRNA Vaccines and Non-COVID-19 mRNA Vaccines

mRNA Type – Nucleoside-Modified mRNA, Unmodified mRNA, and Self-Amplifying mRNA

Regional Segmentation

North America – U.S., and Canada

Europe – Germany, France, U.K., Italy, Spain, and Rest-of-Europe

Asia-Pacific – China, Japan, South Korea, Australia, and Rest-of-Asia-Pacific

Latin America – Brazil, Mexico, and Rest-of-Latin America

Rest-of-the-World

Growth Drivers

Growing Cases of COVID-19 Globally

Favorable Regulatory Environment

Significant External Funding for the Development of mRNA-Based COVID-19 Vaccines

Market Challenges

Logistical Challenges Associated with mRNA-Based COVID-19 Vaccines

High Price Associated with mRNA-Based COVID-19 Vaccines

Market Opportunities

Growing Emphasis on Research and Development for Non-COVID-19 Applications

Key Companies Profiled

Arcturus Therapeutics Holdings Inc., BioNTech SE, CureVac N.V., Daiichi Sankyo Company, Limited., ethris GmbH, GlaxoSmithKline plc, Gennova Biopharmaceuticals Ltd, Moderna, Inc., Pantherna Therapeutics GmbH, Providence Therapeutics, Silence Therapeutics, Translate Bio, VERSAMEB AG, and Verve Therapeutics, Inc.

Key Questions Answered in this Report:

What are the major market drivers, challenges, and opportunities in the global mRNA vaccines and therapeutics market?

What are the key development strategies being implemented by the major players in order to sustain in the competitive market?

What are the key regulatory implications in developed and developing regions for the global mRNA vaccines and therapeutics market?

How is each segment of the market expected to grow during the forecast period, 2021-2031?

Who are the leading players with significant offerings to the global mRNA vaccines and therapeutics market, and what is the expected market dominance for each of these leading players?

What are the adoption trends for mRNA vaccines and therapeutics in established economies and emerging economies across the world?

Which companies are anticipated to be highly disruptive in the future, and why?

What are the current clinical unmet needs that are being faced in the global mRNA vaccines and therapeutics market?

What are the dynamics of various application areas and countries, which are impacting the global mRNA vaccines and therapeutics market?

What are the new market opportunities that are influencing the growth of the global mRNA vaccines and therapeutics market?

How is each segment of the market expected to grow during the forecast period from 2021 to 2031? Following are the segment types:

Application

mRNA Type

Region

What are the unmet needs currently existing in the global mRNA vaccines and therapeutics market?

Market Overview

Global mRNA Vaccines and Therapeutics Market: Focus on Application, mRNA Type, Country Data (13 Countries), an...

BIS healthcare experts have found the mRNA vaccines and therapeutics market to be one of the most rapidly evolving and dynamic markets, and the global market for mRNA vaccines and therapeutics for COVID-19 vaccines is predicted to grow at a CAGR of -13.50% over the forecast period of 2021-2025. Moreover, the global market for mRNA vaccines and therapeutics for non-COVID-19 vaccines is predicted to grow at a CAGR of 95.49% over the forecast period of 2026-2031. The overall global mRNA vaccines and therapeutics market is driven by certain factors, which include growing cases of COVID-19 globally, a favorable regulatory environment, and significant external funding for the development of mRNA-based COVID-19 vaccines.

The growth of the market is favored by the developments in the field of mRNA-based COVID-19 vaccines due to the growing cases of COVID-19 globally, favourable regulatory environment, and significant external funding for the development of mRNA-based COVID-19 vaccines. Additionally, the emergence of the new SARS-CoV-2 virus in different countries, coupled with the efficacy of mRNA vaccines against new strains, are some of the critical factors which are expected to bolster the market growth. Furthermore, pharmaceutical companies are focusing on the development of new mRNA-based vaccine candidates for COVID-19 to support the healthcare authorities and the government to establish robust vaccination strategies.

The market for mRNA vaccines and therapeutics for non-COVID-19 is favored by the clinical developments which have been taking place to develop novel mRNA-based vaccines and therapies for non-COVID-19 applications, particularly for infectious disease, oncology, and other diseases. The emerging and legacy pharmaceutical companies are massively investing in the development of these treatment modalities to further expand their pipeline. The successful launch of these candidates after obtaining regulatory approvals from the regulatory authorities is anticipated to increase the competitiveness of the market.

Within the research report, the market is segmented on the basis of applications, mRNA type, and region. Each of these segments covers the snapshot of the market over the projected years, the inclination of the market revenue, underlying patterns, and trends by using analytics on the primary and secondary data obtained.

Competitive Landscape

The exponential rise in the number of COVID-19 cases followed by the growing emphasis of the government for establishing robust vaccination strategies has created a

buzz among the pharmaceutical companies to further invest in the development of mRNA-based vaccines for COVID-19. Additionally, due to the growing prominence of mRNA vaccines, pharmaceutical companies are also significantly investing to expand their respective pipeline for non-COVID-19 applications such as infectious diseases, oncology, and other diseases. Due to the presence of a diverse portfolio and intense market penetration, BioNTech SE has been a pioneer in the mRNA vaccines and therapeutics ecosystem.

On the basis of region, North America holds the largest share of the mRNA vaccines and therapeutics market for COVID-19 vaccines due to significantly growing fund infusions for mRNA vaccine development, high rise in the pipeline products, presence of established and emerging pharmaceutical companies, presence of ultracold manufacturing and supply chains, and increasing awareness about mRNA-based COVID-19 vaccines, among others. Apart from this, the Asia-Pacific region is anticipated to grow at the fastest rate due to the exponentially rising cases of COVID-19 in the emerging countries, presence of a high population base in the region, and increasing demand for mRNA-based vaccines, among others.

Moreover, North America also holds the largest share of the mRNA vaccines and therapeutics market for non-COVID-19 vaccines due to the growing need to develop transformative therapeutics, increasing fund infusions, a favorable regulatory environment, and massively growing attention to establish precision medicine, among others.

Contents

Executive Summary

1 PRODUCT DEFINITION

1.1 Inclusions and Exclusions

2 MARKET SCOPE

2.1 Scope of Work

2.2 Key Questions Answered in the Report

3 RESEARCH METHODOLOGY

3.1 Global mRNA Vaccines and Therapeutics Market: Research Methodology

3.2 Primary Data Sources

3.3 Secondary Data Sources

3.4 Market Estimation Model

3.5 Criteria for Company Profiling

4 MARKET OVERVIEW

4.1 Market Definition

4.2 Current Landscape and Future Potential of mRNA-Based Vaccines

4.3 Market Footprint and Growth Potential

4.3.1 Global mRNA Vaccines and Therapeutics Market (by COVID-19 Vaccines),
\$Million, 2020-2025

4.3.2 Global mRNA Vaccines and Therapeutics Market (by Non-COVID-19 Vaccines),
\$Million, 2025-2031

5 INDUSTRY INSIGHTS

5.1 Overview

5.2 Legal Requirements and Frameworks in the U.S.

5.2.1 Vaccines

5.2.1.1 Pre-Clinical and Clinical Development

5.2.1.2 Emergency Use Authorization (Public Health Emergencies)

5.2.1.3 Assessment of Manufacturing

- 5.2.1.4 Final Approval
- 5.2.2 Therapeutics
 - 5.2.2.1 Clinical Trial Authorization
 - 5.2.2.2 Marketing Authorization
 - 5.2.2.3 Post-Authorization Regulations
- 5.3 Legal Requirements and Frameworks in Europe
 - 5.3.1 Vaccines
 - 5.3.2 Therapeutics
 - 5.3.2.1 Centralized Procedure
 - 5.3.2.2 Decentralized Procedure
 - 5.3.2.3 Mutual-Recognition Procedure
 - 5.3.2.4 National Procedure
- 5.4 Legal Requirements and Frameworks in Asia-Pacific
 - 5.4.1 China
 - 5.4.2 Japan

6 MARKET DYNAMICS

- 6.1 Overview
- 6.2 Impact Analysis
- 6.3 Market Drivers
 - 6.3.1 Growing Cases of COVID-19 Globally
 - 6.3.2 Favorable Regulatory Environment
 - 6.3.3 Significant External Funding for the Development of mRNA-Based COVID-19 Vaccines
- 6.4 Market Restraints
 - 6.4.1 Logistical Challenges Associated with mRNA-Based COVID-19 Vaccines
 - 6.4.2 High Price Associated with mRNA-Based COVID-19 Vaccines
- 6.5 Opportunities
 - 6.5.1 Growing Emphasis on Research and Development for Non-COVID-19 Applications

7 COMPETITIVE LANDSCAPE

- 7.1 Key Strategies and Developments
 - 7.1.1 Synergistic Activities
 - 7.1.2 Product Approvals and Commercialization
 - 7.1.3 Funding
- 7.2 Market Share Analysis (by Company), 2020-2021

8 GLOBAL MRNA VACCINES AND THERAPEUTICS MARKET (BY APPLICATION)

8.1 COVID-19 mRNA Vaccines

8.1.1 Overview

8.1.2 Commercialized Vaccines

8.1.2.1 mRNA-1273

8.1.2.1.1 Supply Agreements for mRNA-1273

8.1.2.2 BNT162b2

8.1.2.2.1 Supply Agreements for BNT162b2 (COMIRNATY)

8.1.3 Pipeline Vaccines

8.1.3.1 CVnCoV

8.1.3.2 LUNAR-COV19

8.1.3.3 MRT5500

8.1.3.4 DS-5670

8.2 Non-COVID-19 mRNA Vaccines

8.2.1 Overview

8.2.2 Oncology

8.2.3 Infectious Diseases

8.2.4 Other Diseases

9 GLOBAL MRNA VACCINES AND THERAPEUTICS MARKET (BY MRNA TYPE)

9.1 Overview

9.2 COVID-19 (by mRNA Type)

9.2.1 Nucleoside-Modified mRNA (modRNA)

9.2.2 Unmodified mRNA

9.2.3 Self-Amplifying mRNA

9.3 Non-COVID-19 (mRNA Type)

9.3.1 Nucleoside-Modified mRNA (modRNA)

9.3.2 Unmodified mRNA

9.3.3 Self-Amplifying mRNA

10 GLOBAL MRNA VACCINES AND THERAPEUTICS MARKET (BY REGION)

10.1 Overview

10.2 North America

10.2.1 North America mRNA Vaccines and Therapeutics Market (by COVID-19 Vaccines)

10.2.1.1 U.S.

10.2.1.2 Canada

10.2.2 North America mRNA Vaccines and Therapeutics Market (by Non-COVID-19 Vaccines)

10.3 Europe

10.3.1 Europe mRNA Vaccines and Therapeutics Market (by COVID-19 Vaccines)

10.3.1.1 Germany

10.3.1.2 France

10.3.1.3 U.K.

10.3.1.4 Italy

10.3.1.5 Spain

10.3.1.6 Rest-of-Europe

10.3.2 Europe mRNA Vaccines and Therapeutics Market (by Non-COVID-19 Vaccines)

10.4 Asia-Pacific

10.4.1 Asia-Pacific mRNA Vaccines and Therapeutics Market (by COVID-19 Vaccines)

10.4.1.1 China

10.4.1.2 Japan

10.4.1.3 South Korea

10.4.1.4 Australia

10.4.1.5 Rest-of-Asia-Pacific

10.4.2 Asia-Pacific mRNA Vaccines and Therapeutics Market (by Non-COVID-19 Vaccines)

10.5 Latin America

10.5.1 Latin America mRNA Vaccines and Therapeutics Market (by COVID-19 Vaccines)

10.5.1.1 Brazil

10.5.1.2 Mexico

10.5.1.3 Rest-of-Latin America

10.5.2 Latin America mRNA Vaccines and Therapeutics Market (by Non-COVID-19 Vaccines)

10.6 Rest-of-the-World

10.6.1 Rest-of-the-World mRNA Vaccines and Therapeutics Market (by COVID-19 Vaccines)

10.6.2 Rest-of-the-World mRNA Vaccines and Therapeutics Market (by Non-COVID-19 Vaccines)

11 COMPANY PROFILES

11.1 Overview

11.2 Arcturus Therapeutics Holdings Inc.

11.2.1 Company Overview

11.2.2 Role of Arcturus Therapeutics Holdings Inc. in the Global mRNA Vaccines and Therapeutics Market

11.2.3 Financials

11.2.4 Key Insights About Financial Health of the Company

11.2.5 SWOT Analysis

11.3 BioNTech SE

11.3.1 Company Overview

11.3.2 Role of BioNTech SE in the Global mRNA Vaccines and Therapeutics Market

11.3.3 Financials

11.3.4 Key Insights About Financial Health of the Company

11.3.5 SWOT Analysis

11.4 CureVac N.V.

11.4.1 Company Overview

11.4.2 Role of CureVac N.V. in the Global mRNA Vaccines and Therapeutics Market

11.4.3 Financials

11.4.4 Key Insights About Financial Health of the Company

11.4.5 SWOT Analysis

11.5 Daiichi Sankyo Company, Limited.

11.5.1 Company Overview

11.5.2 Role of Daiichi Sankyo Company, Limited. in the Global mRNA Vaccines and Therapeutics Market

11.5.3 Financials

11.5.4 Key Insights About Financial Health of the Company

11.5.5 SWOT Analysis

11.6 ethris GmbH

11.6.1 Company Overview

11.6.2 Role of ethris GmbH in Global mRNA Vaccines and Therapeutics Market

11.6.3 SWOT Analysis

11.7 GlaxoSmithKline plc

11.7.1 Company Overview

11.7.2 Role of GlaxoSmithKline plc in Global mRNA Vaccines and Therapeutics Market

11.7.3 Financials

11.7.4 Key Insights About Financial Health of the Company

11.7.5 SWOT Analysis

11.8 Gennova Biopharmaceuticals Ltd

- 11.8.1 Company Overview
- 11.8.2 Role of Gennova Biopharmaceuticals Ltd in Global mRNA Vaccines and Therapeutics Market
- 11.8.3 SWOT Analysis
- 11.9 Moderna, Inc.
 - 11.9.1 Company Overview
 - 11.9.2 Role of Moderna, Inc. in the Global mRNA Vaccines and Therapeutics Market
 - 11.9.3 Financials
 - 11.9.4 Key Insights About Financial Health of the Company
 - 11.9.5 SWOT Analysis
- 11.1 Pantherna Therapeutics GmbH
 - 11.10.1 Company Overview
 - 11.10.2 Role of Pantherna Therapeutics GmbH in Global mRNA Vaccines and Therapeutics Market
 - 11.10.3 SWOT Analysis
- 11.11 Providence Therapeutics
 - 11.11.1 Company Overview
 - 11.11.2 Role of Providence Therapeutics in Global mRNA Vaccines and Therapeutics Market
 - 11.11.3 SWOT Analysis
- 11.12 Silence Therapeutics
 - 11.12.1 Company Overview
 - 11.12.2 Role of Silence Therapeutics in the Global mRNA Vaccines and Therapeutics Market
 - 11.12.3 Financials
 - 11.12.4 Key Insights About Financial Health of the Company
 - 11.12.5 SWOT Analysis
- 11.13 Translate Bio
 - 11.13.1 Company Overview
 - 11.13.2 Role of Translate Bio in the Global mRNA Vaccines and Therapeutics Market
 - 11.13.3 Financials
 - 11.13.4 Key Insights About Financial Health of the Company
 - 11.13.5 SWOT Analysis
- 11.14 VERSAMEB AG
 - 11.14.1 Company Overview
 - 11.14.2 Role of VERSAMEB AG in the Global mRNA Vaccines and Therapeutics Market
 - 11.14.3 SWOT Analysis
- 11.15 Verve Therapeutics, Inc.

11.15.1 Company Overview

11.15.2 Role of Verve Therapeutics, Inc. in the Global mRNA Vaccines and Therapeutics Market

11.15.3 SWOT Analysis

List Of Tables

LIST OF TABLES

Table 6.1: Likert Scale

Table 6.2: Impact Analysis of Market Drivers

Table 6.3: Impact Analysis of Market Restraints

Table 8.1: mRNA Vaccines and Therapeutics for Oncology (Pipeline)

Table 8.2: mRNA Vaccines and Therapeutics for Infectious Diseases (Pipeline)

Table 8.3: mRNA Vaccines and Therapeutics for Other Diseases (Pipeline)

List Of Figures

LIST OF FIGURES

Figure 1: Cumulative COVID-19 Cases (as of April 18, 2021)

Figure 2: Impact Analysis of Market Drivers and Market Challenges on Global mRNA Vaccines and Therapeutics Market

Figure 3: Global mRNA Vaccines and Therapeutics Market for COVID-19 Vaccines (Commercialized), Q4 2020 Vs. Q4 2025

Figure 4: Global mRNA Vaccines and Therapeutics Market for COVID-19 Vaccines (Pipeline), Q2 2021 Vs. Q4 2025

Figure 5: Global mRNA Vaccines and Therapeutics Market for Non-COVID-19 Vaccines (Pipeline), 2025 Vs. 2031

Figure 6: Global mRNA Vaccines and Therapeutics Market (by mRNA Type)

Figure 7: Global mRNA Vaccines and Therapeutics Market for COVID-19 Vaccines (by Region), 2020-2025

Figure 8: Global mRNA Vaccines and Therapeutics Market for Non-COVID-19 Vaccines (by Region), 2025-2031

Figure 2.1: Global mRNA Vaccines and Therapeutics, Market Segmentation

Figure 3.1: Global mRNA Vaccines and Therapeutics Market Research Methodology

Figure 3.2: Primary Research Methodology

Figure 3.3: Bottom-Up Approach (Segment-Wise Analysis)

Figure 3.4: Top-Down Approach (Segment-Wise Analysis)

Figure 4.1: Global Revenue for COVID-19 mRNA Vaccines, 2020-2025

Figure 4.2: Global mRNA Vaccines and Therapeutics Market (by Non-COVID-19 Vaccines), 2025-2031

Figure 5.1: Steps for Obtaining Marketing Authorization

Figure 5.2: Vaccine Development Stages

Figure 5.3: Steps for Obtaining EMA Approval for Vaccines

Figure 6.1: Cumulative COVID-19 Cases (as of April 18, 2021)

Figure 6.2: Logistical Challenge Pertaining to mRNA-Based COVID-19 Vaccines

Figure 7.1: Share of Key Developments and Strategies, January 2018-March 2021

Figure 7.2: Share of Synergistic Activities (by Company), January 2018-March 2021

Figure 7.3: Share of Product Approvals and Commercialization (by Company), January 2018-March 2021

Figure 7.4: Share of Funding (by Company), January 2018-March 2021

Figure 7.5: Market Share Analysis for Global mRNA Vaccines and Therapeutics Market, 2020 and 2021

Figure 8.1: Global Revenue for COVID-19 mRNA Vaccines, \$Million, 2020-2025

Figure 8.2: Global Revenue for COVID-19 mRNA Vaccines (Commercialized), \$Million, Q4 2020-Q4 2025

Figure 8.3: Global Revenue for COVID-19 mRNA Vaccines (mRNA-1273), \$Million, Q4 2020-Q4 2025

Figure 8.4: Global Revenue for COVID-19 mRNA Vaccines (BNT162b2), \$Million, Q4 2020-Q4 2025

Figure 8.5: Expected Revenue from mRNA-Based COVID-19 Vaccines (Pipeline), \$Million, Q4 2020-Q4 2025

Figure 8.6: Global Estimated Revenue for CVnCoV, \$Million, Q2 2021- Q4 2025

Figure 8.7: Global Estimated Revenue for LUNAR-COV19, \$Million, Q3 2022-Q4 2025

Figure 8.8: Global Estimated Revenue for MRT5500, \$Million, Q4 2022-Q4 2025

Figure 8.9: Global Estimated Revenue for DS-5670, \$Million, Q4 2022-Q4 2025

Figure 8.10: Global mRNA Vaccines and Therapeutics Market (by Non-COVID-19 Vaccines)

Figure 8.11: Global mRNA Vaccines and Therapeutics Market (by Non-COVID-19 Vaccines), 2025-2031

Figure 8.12: Global mRNA Vaccines and Therapeutics Market (Oncology), \$Million, 2025-2031

Figure 8.13: Global mRNA Vaccines and Therapeutics Market (Infectious Diseases), \$Million, 2025-2031

Figure 8.14: Global mRNA Vaccines and Therapeutics Market (Other Diseases), \$Million, 2025-2031

Figure 9.1: Global mRNA Vaccines and Therapeutics Market (by mRNA Type)

Figure 9.2: Global mRNA Vaccines and Therapeutics Market for COVID-19 (Nucleoside-Modified mRNA), \$Million, Q42020-Q42025

Figure 9.3: Global mRNA Vaccines and Therapeutics Market for COVID-19 (Unmodified mRNA), \$Million, Q2 2021-Q4 2025

Figure 9.4: Global mRNA Vaccines and Therapeutics Market for COVID-19 (Self-Amplifying mRNA), \$Million, Q3 2022-Q4 2025

Figure 9.5: Global mRNA Vaccines and Therapeutics Market for Non-COVID-19 (Nucleoside-Modified mRNA), \$Million, 2025-2031

Figure 9.6: Global mRNA Vaccines and Therapeutics Market for Non-COVID-19 (Unmodified mRNA), \$Million, 2025-2031

Figure 9.7: Global mRNA Vaccines and Therapeutics Market for Non-COVID-19 (Self-Amplifying mRNA), \$Million, 2029-2031

Figure 10.1: Global mRNA Vaccines and Therapeutics Market for COVID-19 Vaccines (by Region), 2020 and 2025

Figure 10.2: Global mRNA Vaccines and Therapeutics Market for Non-COVID-19 Vaccines (by Region), 2025 and 2031

Figure 10.3: North America: Market Dynamics

Figure 10.4: North America mRNA Vaccines and Therapeutics Market (by COVID-19 Vaccines), \$Million, Q4 2020 vs. Q4 2025

Figure 10.5: North America mRNA Vaccines and Therapeutics Market (COVID-19 Vaccines), (by Country), \$Million, Q4 2020 vs. Q4 2025

Figure 10.6: U.S. mRNA Vaccines and Therapeutics Market (by COVID-19 Vaccines), \$Million, Q4 2020-Q4 2025

Figure 10.7: Canada mRNA Vaccines and Therapeutics Market (by COVID-19 Vaccines), \$Million, Q4 2020-Q4 2025

Figure 10.8: North America mRNA Vaccines and Therapeutics Market (by Non-COVID-19 Vaccines), \$Million, 2025-2031

Figure 10.9: Europe: Market Dynamics

Figure 10.10: Europe mRNA Vaccines and Therapeutics Market (by COVID-19 Vaccines), \$Million, Q4 2020-Q4 2025

Figure 10.11: Europe mRNA Vaccines and Therapeutics Market (COVID-19 Vaccines), (by Country), \$Million, Q4 2020 vs. Q4 2025

Figure 10.12: Germany mRNA Vaccines and Therapeutics Market (by COVID-19 Vaccines), \$Million, Q4 2020-Q4 2025

Figure 10.13: France mRNA Vaccines and Therapeutics Market (by COVID-19 Vaccines), \$Million, Q4 2020-Q4 2025

Figure 10.14: U.K. mRNA Vaccines and Therapeutics Market (by COVID-19 Vaccines), \$Million, Q4 2020-Q4 2025

Figure 10.15: Italy mRNA Vaccines and Therapeutics Market (by COVID-19 Vaccines), \$Million, Q4 2020-Q4 2025

Figure 10.16: Spain mRNA Vaccines and Therapeutics Market (by COVID-19 Vaccines), \$Million, Q4 2020-Q4 2025

Figure 10.17: Rest-of-Europe mRNA Vaccines and Therapeutics Market (by COVID-19 Vaccines), \$Million, Q1 2020-Q4 2025

Figure 10.18: Europe mRNA Vaccines and Therapeutics (by Non-COVID-19 Vaccines), \$Million, 2025-2031

Figure 10.19: Asia-Pacific: Market Dynamics

Figure 10.20: Asia-Pacific mRNA Vaccines and Therapeutics Market (by COVID-19 Vaccines), \$Million, Q4 2020-Q4 2025

Figure 10.21: Asia-Pacific mRNA Vaccines and Therapeutics Market (COVID-19 Vaccines), (by Country), \$Million, Q1 2021 vs. Q4 2025

Figure 10.22: China mRNA Vaccines and Therapeutics Market (by COVID-19 Vaccines), \$Million, Q2 2021-Q4 2025

Figure 10.23: Japan mRNA Vaccines and Therapeutics Market (by COVID-19 Vaccines), \$Million, Q1 2021-Q4 2025

Figure 10.24: South Korea mRNA Vaccines and Therapeutics Market (by COVID-19 Vaccines), \$Million, Q2 2021-Q4 2025

Figure 10.25: Australia mRNA Vaccines and Therapeutics Market (by COVID-19 Vaccines), \$Million, Q1 2021-Q4 2025

Figure 10.26: Rest-of-Asia-Pacific mRNA Vaccines and Therapeutics Market (by COVID-19 Vaccines), \$Million, Q1 2021-Q4 2025

Figure 10.27: Asia-Pacific mRNA Vaccines and Therapeutics Market (by Non-COVID-19 Vaccines), \$Million, 2026-2031

Figure 10.28: Latin America: Market Dynamics

Figure 10.29: Latin America mRNA Vaccines and Therapeutics Market (COVID-19 Vaccines), (by Country), \$Million, Q1 2021 vs. Q4 2025

Figure 10.30: Latin America mRNA Vaccines and Therapeutics Market (by COVID-19 Vaccines), \$Million, Q4 2020-Q4 2025

Figure 10.31: Brazil mRNA Vaccines and Therapeutics Market (by COVID-19 Vaccines), \$Million, Q1 2021-Q4 2025

Figure 10.32: Mexico mRNA Vaccines and Therapeutics Market (by COVID-19 Vaccines), \$Million, Q1 2021-Q4 2025

Figure 10.33: Rest-of-Latin America mRNA Vaccines and Therapeutics Market (by COVID-19 Vaccines), \$Million, Q1 2021-Q4 2025

Figure 10.34: Latin America mRNA Vaccines and Therapeutics Market (by Non-COVID-19 Vaccines), \$Million, 2026-2031

Figure 10.35: Rest-of-the-World mRNA Vaccines and Therapeutics Market (by COVID-19 Vaccines), \$Million, Q4 2020-Q4 2025

Figure 10.36: Rest-of-the-World mRNA Vaccines and Therapeutics (by Non-COVID-19 Vaccines), \$Million, 2026-2031

Figure 11.1: Total Number of Companies Profiled

Figure 11.2: Arcturus Therapeutics Holdings Inc.: Pipeline Portfolio

Figure 11.3: Arcturus Therapeutics Holdings Inc.: Overall Financials, 2018-2020

Figure 11.4: Arcturus Therapeutics Holdings Inc.: R&D Expenditure, 2018-2020

Figure 11.5: Arcturus Therapeutics Holdings Inc.: SWOT Analysis

Figure 11.6: BioNTech SE: Product Portfolio

Figure 11.7: BioNTech SE: Pipeline Portfolio

Figure 11.8: BioNTech SE: Overall Financials, 2018-2020

Figure 11.9: BioNTech SE: Revenue (by Segment), 2018-2020

Figure 11.10: BioNTech SE: R&D Expenditure, 2018-2020

Figure 11.11: BioNTech SE: SWOT Analysis

Figure 11.12: CureVac N.V.: Pipeline Portfolio

Figure 11.13: CureVac N.V.: Overall Financials, 2018-2019

Figure 11.14: CureVac N.V.: Revenue (by Region), 2018-2019

- Figure 11.15: CureVac N.V.: R&D Expenditure, 2018-2019
- Figure 11.16: CureVac N.V.: SWOT Analysis
- Figure 11.17: Daiichi Sankyo Company, Limited: Pipeline Portfolio
- Figure 11.18: Daiichi Sankyo Company, Limited: Overall Financials, 2017-2019
- Figure 11.19: Daiichi Sankyo Company, Limited.: Revenue (by Segment), 2017-2019
- Figure 11.20: Daiichi Sankyo Company, Limited.: Revenue (by Region), 2017-2019
- Figure 11.21: Daiichi Sankyo Company, Limited: R&D Expenditure, 2017-2019
- Figure 11.22: Daiichi Sankyo Company, Limited.: SWOT Analysis
- Figure 11.23: ethris GmbH: Pipeline Portfolio
- Figure 11.24: ethris GmbH: SWOT Analysis
- Figure 11.25: GlaxoSmithKline plc: Pipeline Portfolio
- Figure 11.26: GlaxoSmithKline plc: Overall Financials, 2018-2020
- Figure 11.27: GlaxoSmithKline plc: Revenue (by Segment), 2018-2020
- Figure 11.28: GlaxoSmithKline plc: Revenue (by Region), 2018-2020
- Figure 11.29: GlaxoSmithKline plc: R&D Expenditure, 2018-2020
- Figure 11.30: GlaxoSmithKline plc: SWOT Analysis
- Figure 11.31: Gennova Biopharmaceuticals Ltd: Pipeline Portfolio
- Figure 11.32: Gennova Biopharmaceuticals Ltd: SWOT Analysis
- Figure 11.33: Moderna, Inc.: Product Portfolio
- Figure 11.34: Moderna, Inc: Pipeline Portfolio
- Figure 11.35: Moderna, Inc.: Overall Financials, 2018-2020
- Figure 11.36: Moderna, Inc.: Revenue (by Segment), 2018-2020
- Figure 11.37: Moderna, Inc.: Revenue (by Region), 2020
- Figure 11.38: Moderna, Inc.: R&D Expenditure, 2018-2020
- Figure 11.39: Moderna, Inc.: SWOT Analysis
- Figure 11.40: Pantherna Therapeutics GmbH: Pipeline Portfolio
- Figure 11.41: Pantherna Therapeutics GmbH: SWOT Analysis
- Figure 11.42: Providence Therapeutics: Pipeline Portfolio
- Figure 11.43: Providence Therapeutics: SWOT Analysis
- Figure 11.44: Silence Therapeutics: Pipeline Portfolio
- Figure 11.45: Silence Therapeutics: Overall Financials, 2019-2020
- Figure 11.46: Silence Therapeutics: Revenue (by Segment), 2019-2020
- Figure 11.47: Silence Therapeutics: Revenue (by Region), 2019-2020
- Figure 11.48: Silence Therapeutics: R&D Expenditure, 2019-2020
- Figure 11.49: Silence Therapeutics: SWOT Analysis
- Figure 11.50: Translate Bio: Pipeline Portfolio
- Figure 11.51: Translate Bio: Overall Financials, 2018-2020
- Figure 11.52: Translate Bio: R&D Expenditure, 2018-2020
- Figure 11.53: Translate Bio: SWOT Analysis

Figure 11.54: VERSAMEB AG: Pipeline Portfolio

Figure 11.55: VERSAMEB AG: SWOT Analysis

Figure 11.56: Verve Therapeutics, Inc.: Pipeline Portfolio

Figure 11.57: Verve Therapeutics, Inc.: SWOT Analysis

I would like to order

Product name: Global mRNA Vaccines and Therapeutics Market: Focus on Application, mRNA Type, Country Data (13 Countries), and Competitive Landscape - Analysis and Forecast, 2021-2031

Product link: <https://marketpublishers.com/r/G6B8AC84A84DEN.html>

Price: US\$ 5,250.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G6B8AC84A84DEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970